Apoptotic cells induce dendritic cell-mediated suppression via interferon-γ-induced IDO

Centre for Research in Biomedicine, Faculty of Applied Sciences, University of the West of England, Bristol BS16 1QY, United Kingdom.
Immunology (Impact Factor: 3.8). 06/2008; 124(1):89-101. DOI: 10.1111/j.1365-2567.2007.02743.x
Source: PubMed


Dendritic cells (DC) are sensitive to their local environment and are affected by proximal cell death. This study investigated the modulatory effect of cell death on DC function. Monocyte-derived DC exposed to apoptotic Jurkat or primary T cells failed to induce phenotypic maturation of the DC and were unable to support CD4+ allogeneic T-cell proliferation compared with DC exposed to lipopolysaccharide (LPS) or necrotic cells. Apoptotic cells coincubated with LPS- or necrotic cell-induced mature DC significantly suppressed CD80, CD86 and CD83 and attenuated LPS-induced CD4+ T-cell proliferation. Reduced levels of interleukin-12 (IL-12), IL-10, IL-6, tumour necrosis factor-alpha and interferon-gamma (IFN-gamma) were found to be concomitant with the suppressive activity of apoptotic cells upon DC. Furthermore, intracellular staining confirmed IFN-gamma expression by DC in association with apoptotic environments. The specific generation of IFN-gamma by DC within apoptotic environments is suggestive of an anti-inflammatory role by the induction of indoleamine 2,3-dioxygenase (IDO). Both neutralization of IFN-gamma and IDO blockade demonstrated a role for IFN-gamma and IDO in the suppression of CD4+ T cells. Moreover, we demonstrate that IDO expression within the DC was found to be IFN-gamma-dependent. Blocking transforming growth factor-beta (TGF-beta) also produced a partial release in T-cell proliferation. Our study strongly suggests that apoptosis-induced DC suppression is not an immunological null event and two prime mediators underpinning these functional effects are IFN-gamma-induced IDO and TGF-beta.

Download full-text


Available from: Rachel A Harry, Oct 04, 2015
17 Reads
  • Source
    • "Several reports have shown that interaction and/or internalization of apoptotic cells by immature DCs does not induce expression of the DC maturation-markers MHC class II, CD40, CD80, CD86, and CD83 in vitro or in vivo, even after challenge with LPS, CD40 signaling, TNF-α, or monocyte-conditioned medium [143–146]. Additionally, DCs that internalize cells in early apoptosis exhibit a selective decrease in the levels of mRNA and secretion of the proinflammatory cytokines IL-1α, IL-1β, IL-6, IL-12p70, and TNF-α, while secreting normal or increased amounts of immunosuppressive transforming growth factor (TGF)-β1 and IL-10, even in the presence of LPS [147–149]. DCs that acquire antigens from apoptotic cells efficiently present apoptotic cell-derived peptides to CD4 T cells and cross-present the internalized antigen to MHC class I-restricted CD8 cytotoxic T cells [150–153]. However, DCs exposed to apoptotic cells show a decrease in their ability to stimulate T cells, a phenomenon that seems to be related to the inhibitory effect of apoptotic cells on the amount of expression of MHC and costimulatory molecules, rather than to a defect in the antigen processing function of the APC [132, 144, 145, 154]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: One of the greatest advances in medicine during the past century is the introduction of organ transplantation. This therapeutic strategy designed to treat organ failure and organ dysfunction allows to prolong the survival of many patients that are faced with no other treatment option. Today, organ transplantation between genetically dissimilar individuals (allogeneic grafting) is a procedure widely used as a therapeutic alternative in cases of organ failure, hematological disease treatment, and some malignancies. Despite the potential of organ transplantation, the administration of immunosuppressive drugs required for allograft acceptance induces severe immunosuppression in transplanted patients, which leads to serious side effects such as infection with opportunistic pathogens and the occurrence of neoplasias, in addition to the known intrinsic toxicity of these drugs. To solve this setback in allotransplantation, researchers have focused on manipulating the immune response in order to create a state of tolerance rather than unspecific immunosuppression. Here, we describe the different treatments and some of the novel immunotherapeutic strategies undertaken to induce transplantation tolerance.
    Clinical and Developmental Immunology 05/2013; 2013(5062):210506. DOI:10.1155/2013/210506 · 2.93 Impact Factor
  • Source
    • "It has been demonstrated that a distinct group of DCs with suppressive function emerge after exposure to certain cytokines or when the DCs re-differentiation in different stromal microenvironments [3], [4], [5]. The cytokines or factors produced by DCs, such as transforming growth factor-beta (TGF-beta), IL-10, indoleamine 2,3-dioxygenase (IDO), and NO, may play an important role in the regulation of immune responses [1], [6], [7], [8], [9]. In our previous studies, we demonstrated that NO production is a significant characteristic of regulatory DCs derived from mature DCs co-cultured with splenic or hepatic stroma [3], [10] and that this NO exerts direct, rapid and potent inhibitory effects on T cell proliferation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The contraction phase of antigen-specific immune responses involves the apoptotic loss of numerous activated lymphocytes. While apoptotic cells are known to induce immune suppression, the mechanisms involved therein are still ambiguous. Some reports have speculated that macrophages can induce regulatory T cells (Tregs) after engulfing apoptotic cells. In this study, we showed that dendritic cells (DCs) that phagocytose apoptotic T cells acquire inhibitory function (named DCapos) toward CD4(+) and CD8(+) T cells. These inhibitory DCs could not induce the generation of Tregs, but they were found to directly inhibit mDCs that initiate CD4(+) and CD8(+) T cell proliferation both in vitro and in vivo. Soluble factors including NO play a role in the DCapos-induced suppression of CD4(+) and CD8(+) T cell proliferation. Further results showed that STAT3 phosphorylation and inducible nitric oxide synthase (iNOS) generation were enhanced when DCs were co-cultured with apoptotic cells. Both iNOS transcription and NO secretion were inhibited in the presence of the specific p-STAT3 inhibitor JSI-124. All the data indicated that apoptotic cells could turn DCs to inhibitory DCs, which might play important roles in the suppression of immune responses. STAT3 activation and the consequent release of NO are responsible for the inhibitory functions of DCapos.
    PLoS ONE 11/2012; 7(11):e49378. DOI:10.1371/journal.pone.0049378 · 3.23 Impact Factor
  • Source
    • "Uptake of dying cells generated under normal homeostatic conditions inhibits maturation and pro-inflammatory cytokine production in the phagocytosing DC. In addition, the uptake of these apoptotic cells has been shown to induce immunoregulatory factors that dampen adaptive immune responses, including IL-10, transforming growth factor-β (TGF-β), and prostaglandin E2 [84-87]. This “tolerogenic” state has been shown to become entrenched in the DC program and, as a result, DC respond poorly or in an immune-suppressive fashion to subsequent immunostimulatory agents. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Dendritic cells (DC) are professional antigen presenting cells that are crucial for the induction of anti-tumor T cell responses. As a consequence, research has focused on the harnessing of DCs for therapeutic interventions. Although current strategies employing ex vivo-generated and tumor-antigen loaded DCs have been proven feasible, there are still many obstacles to overcome in order to improve clinical trial successes and offset the cost and complexity of customized cell therapy. This review focuses on one of these obstacles and a pivotal step for the priming of tumor-specific CD8+ and CD4+ T cells; the in vitro loading of DCs with tumor antigens.
    Cancers 12/2011; 3(2):2195-213. DOI:10.3390/cancers3022195
Show more